Incyte's Meury, now a buyer, sees $2B Vega deal as a step in blood treatments beyond Jakafi

Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY

Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s.